Andy Shah's questions to Altimmune Inc (ALT) leadership • Q1 2025
Question
Andy Shah of William Blair inquired about the degree of overlap between the clinical trial sites used for the MASH and obesity programs and the sites planned for the upcoming AUD and ALD trials.
Answer
An Altimmune executive stated that while there is 'some overlap' between the site networks due to the commonality of obesity in these patient populations, he could not provide specific data on the percentage of overlapping sites at this time.